Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lixisenatide
- Development stage
- Approved
- Lead developer
- Sanofi
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
Lixisenatide is a once-daily injectable peptide drug used to treat type 2 diabetes mellitus. It is a glucagon-like peptide-1 (GLP-1) receptor agonist, also known as an incretin mimetic. Lixisenatide works by stimulating the pancreas to secrete insulin in response to high blood glucose levels, decreasing glucagon secretion, and slowing gastric emptying. These actions help lower postprandial and fasting blood glucose levels and may contribute to weight loss. Lixisenatide is not indicated for type 1 diabetes or as a substitute for insulin in patients requiring insulin therapy. The drug was developed by Sanofi and is marketed under the brand names Adlyxin (US) and Lyxumia (EU).
- Brand names
- AdlyxinLyxumia
- Other names
- des-38-proline-exendine-4 (Heloderma suspectum)-(1-39)-peptidylpenta-L-lysyl-L-lysinamide
02
Targets
Beyond the preview
Go deeper on lixisenatide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lixisenatide.